Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

355 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Potential mechanisms of how B-cell depletion works in MOGAD.
Bilodeau PA, Yeh A, Lechner-Scott J, Hawkes CH, Giovannoni G, Levy M. Bilodeau PA, et al. Among authors: lechner scott j. Mult Scler Relat Disord. 2025 Jan 14;93:106269. doi: 10.1016/j.msard.2025.106269. Online ahead of print. Mult Scler Relat Disord. 2025. PMID: 39827742 No abstract available.
Repurposing Licensed Drugs with Activity Against Epstein-Barr Virus for Treatment of Multiple Sclerosis: A Systematic Approach.
Li V, McKay FC, Tscharke DC, Smith C, Khanna R, Lechner-Scott J, Rawlinson WD, Lloyd AR, Taylor BV, Morahan JM, Steinman L, Giovannoni G, Bar-Or A, Levy M, Drosu N, Potter A, Caswell N, Smith L, Brady EC, Frost B, Hodgkinson S, Hardy TA, Broadley SA; Australian Anti-EBV Drugs for MS Working Group. Li V, et al. Among authors: lechner scott j. CNS Drugs. 2025 Jan 10. doi: 10.1007/s40263-024-01153-5. Online ahead of print. CNS Drugs. 2025. PMID: 39792343
Author Correction: A deep catalogue of protein-coding variation in 983,578 individuals.
Sun KY, Bai X, Chen S, Bao S, Zhang C, Kapoor M, Backman J, Joseph T, Maxwell E, Mitra G, Gorovits A, Mansfield A, Boutkov B, Gokhale S, Habegger L, Marcketta A, Locke AE, Ganel L, Hawes A, Kessler MD, Sharma D, Staples J, Bovijn J, Gelfman S, Di Gioia A, Rajagopal VM, Lopez A, Varela JR, Alegre-Díaz J, Berumen J, Tapia-Conyer R, Kuri-Morales P, Torres J, Emberson J, Collins R; Regeneron Genetics Center; RGC-ME Cohort Partners; Cantor M, Thornton T, Kang HM, Overton JD, Shuldiner AR, Cremona ML, Nafde M, Baras A, Abecasis G, Marchini J, Reid JG, Salerno W, Balasubramanian S. Sun KY, et al. Nature. 2025 Jan 8. doi: 10.1038/s41586-024-08571-x. Online ahead of print. Nature. 2025. PMID: 39779867 No abstract available.
Correction: Estimation of Transition Probabilities from a Large Cohort (> 6000) of Australians Living with Multiple Sclerosis (MS) for Changing Disability Severity Classifications, MS Phenotype, and Disease-Modifying Therapy Classifications.
Campbell JA, Henson GJ, Ngwa VF, Ahmad H, Taylor BV, van der Mei I; MSBase Australian Researchers; Palmer AJ. Campbell JA, et al. Pharmacoeconomics. 2024 Dec 30. doi: 10.1007/s40273-024-01461-0. Online ahead of print. Pharmacoeconomics. 2024. PMID: 39739244 No abstract available.
Longitudinal trajectories of digital upper limb biomarkers for multiple sclerosis.
Foong YC, Merlo D, Gresle M, Zhu C, Buzzard K, Lechner-Scott J, Barnett M, Taylor BV, Kalincik T, Kilpatrick T, Darby D, Dobay P, van Beek J, Hyde R, Simpson-Yap S, Butzkueven H, van der Walt A. Foong YC, et al. Among authors: lechner scott j. Eur J Neurol. 2025 Jan;32(1):e70000. doi: 10.1111/ene.70000. Eur J Neurol. 2025. PMID: 39714314 Free PMC article.
Improvements in quality of life of people with relapsing multiple sclerosis treated with cladribine tablets during the 2-year CLARIFY-MS study: a plain language summary.
Brochet B, Solari A, Lechner-Scott J, Piehl F, Langdon D, Hupperts R, Selmaj K, Patti F, Brieva L, Maidal EM, Alexandri N, Smyk A, Nolting A, Montalban X, Kubala Havrdova E. Brochet B, et al. Among authors: lechner scott j. Neurodegener Dis Manag. 2024;14(6):193-201. doi: 10.1080/17582024.2024.2429970. Epub 2024 Dec 16. Neurodegener Dis Manag. 2024. PMID: 39676554 Free PMC article.
Disease-modifying treatment and disability progression in subclasses of patients with primary progressive MS: results from the Big MS Data Network.
Lorscheider J, Signori A, Subramaniam S, Benkert P, Vukusic S, Trojano M, Hillert J, Glaser A, Hyde R, Spelman T, Magyari M, Elberling F, Pontieri L, Koch-Henriksen N, Sørensen PS, Gerlach O, Prat A, Girard M, Eichau S, Grammond P, Horakova D, Ramo-Tello C, Roos I, Buzzard K, Lechner Scott J, Sánchez-Menoyo JL, Alroughani R, Prévost J, Kuhle J, Gray O, Mathey G, Michel L, Ciron J, De Sèze J, Maillart E, Ruet A, Labauge P, Zephir H, Kwiatkowski A, van der Walt A, Kalincik T, Butzkueven H; Italian MS Register; Observatoire Français de la Sclérose en Plaques (OFSEP); MSBase Study Group; Swedish MS Registry; Big MS Data Network. Lorscheider J, et al. Among authors: lechner scott j. J Neurol Neurosurg Psychiatry. 2024 Dec 6:jnnp-2024-334700. doi: 10.1136/jnnp-2024-334700. Online ahead of print. J Neurol Neurosurg Psychiatry. 2024. PMID: 39643429 Free article.
Prevalence of Progression Independent of Relapse Activity and Relapse-Associated Worsening in Patients With AQP4-IgG-Positive NMOSD.
Siriratnam P, Huda S, Van Der Walt A, Sanfilippo PG, Sharmin S, Foong YC, Yeh WZ, Zhu C, Khoury SJ, Csepany T, Willekens B, Etemadifar M, Ozakbas S, Nytrova P, Altintas A, Al-Asmi A, Ramo-Tello CM, Laureys G, Patti F, Horakova D, Foschi M, Boz C, Mccombe PA, Turkoglu R, Lechner-Scott J, Roos I, Kalincik T, Jokubaitis VG, Butzkueven H, Monif M; for MSBase. Siriratnam P, et al. Among authors: lechner scott j. Neurology. 2024 Dec 24;103(12):e209940. doi: 10.1212/WNL.0000000000209940. Epub 2024 Nov 19. Neurology. 2024. PMID: 39561307
355 results